These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 19844179)
1. Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management. Chen MK; Doddamane I; Cheng DW Curr Opin Oncol; 2010 Jan; 22(1):6-10. PubMed ID: 19844179 [TBL] [Abstract][Full Text] [Related]
2. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638 [TBL] [Abstract][Full Text] [Related]
4. Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin. Zanotti-Fregonara P; Toubert ME; Taieb D; Ravasi L; Rubello D; Hindie E Minerva Endocrinol; 2008 Jun; 33(2):53-65. PubMed ID: 18332849 [TBL] [Abstract][Full Text] [Related]
5. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion. Schlumberger MJ; Incerti C; Pacini F; Reiners C J Endocrinol Invest; 1999; 22(11 Suppl):35-41. PubMed ID: 10727004 [TBL] [Abstract][Full Text] [Related]
6. Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution. Wong R; Topliss DJ; Bach LA; Hamblin PS; Kalff V; Long F; Stockigt JR Intern Med J; 2009 Mar; 39(3):156-63. PubMed ID: 19383064 [TBL] [Abstract][Full Text] [Related]
7. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131. Reiners C; Luster M; Lassmann M J Endocrinol Invest; 1999; 22(11 Suppl):17-24. PubMed ID: 10727001 [TBL] [Abstract][Full Text] [Related]
8. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378 [TBL] [Abstract][Full Text] [Related]
9. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. Perros P J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003 [TBL] [Abstract][Full Text] [Related]
10. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. Schlumberger M; Ricard M; De Pouvourville G; Pacini F Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):641-50. PubMed ID: 17710085 [TBL] [Abstract][Full Text] [Related]
11. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678 [TBL] [Abstract][Full Text] [Related]
12. The use of thyrogen in the treatment of differentiated thyroid carcinoma: an intraindividual comparison of clinical effects and implications of daily life. Dueren C; Dietlein M; Luster M; Plenzig F; Steinke R; Grimm J; Groth P; Eichhorn W; Reiners C Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):513-9. PubMed ID: 19856258 [TBL] [Abstract][Full Text] [Related]
14. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I. Menzel C; Kranert WT; Döbert N; Diehl M; Fietz T; Hamscho N; Berner U; Grünwald F J Nucl Med; 2003 Jul; 44(7):1065-8. PubMed ID: 12843221 [TBL] [Abstract][Full Text] [Related]
15. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499 [TBL] [Abstract][Full Text] [Related]
16. Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods. Vallejo Casas JA; Mena Bares LM; Gálvez MA; Marlowe RJ; Latre Romero JM; Martínez-Paredes M Nucl Med Commun; 2011 Sep; 32(9):840-6. PubMed ID: 21691237 [TBL] [Abstract][Full Text] [Related]
17. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246 [TBL] [Abstract][Full Text] [Related]
18. Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when. Barbaro D; Boni G Eur J Surg Oncol; 2007 Jun; 33(5):535-40. PubMed ID: 17337154 [TBL] [Abstract][Full Text] [Related]
19. Using recombinant human thyroid-stimulating hormone for the diagnosis of recurrent thyroid cancer. Blamey S; Barraclough B; Delbridge L; Mernagh P; Standfield L; Weston A ANZ J Surg; 2005; 75(1-2):10-20. PubMed ID: 15740509 [TBL] [Abstract][Full Text] [Related]
20. Absence of bone marrow toxicity in elderly patients treated with recombinant human thyroid-stimulating hormone and empirically dosed radioiodine for thyroid cancer. Amdur RJ; Dan T; Mazzaferri E Am J Clin Oncol; 2013 Aug; 36(4):348-53. PubMed ID: 22547013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]